Navigation Links
MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug"

MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and preventing them from receiving optimal treatment for Parkinson's.

Flibanserin is a 5-HT1a agonist and a 5-HT2a antagonist and thus fits in with the current theory on levodopa-induced dysinesia that dyskinesia is caused by the release of dopamine from serotonergic neurons. MONITORING FORCE is preparing to file another orphan drug status application with the United States Food and Drug Administration (FDA) and expects the first clinical trial in Parkinson's patients to start by mid-2010.

MONITORING FORCE GmbH is a clinical research company based in Munster/Germany with affiliates in the United States, France, Italy and other countries. MONITORING FORCE does contract research for the pharmaceutical industry as well as re-purposing drug development projects on their own. MONITORING FORCE has been founded in Germany in 1995 and spread to other countries since. Parkinson's disease is a primary focus of the company.

    Contact (Company): Dr. Jurgen Beck

    General Manager, MONITORING FORCE GmbH
    Bahnhofstrasse 111, 48143 Munster, Germany
    Tel.: +49-251-214-01-30, +49-251-26-39-577 (DD)
    Fax: +49-251-21-401-53-9, Mobile: +49-171-869-82-40,  target='_blank' title='


    Contact (Media): Aysun Ertan
    Project Manager, Targa Communications
    Goethestrasse 22, 60313 Frankfurt am Main, Germany
    Tel.: +49-69-66-36-83-98, Fax: +49-69-66-36-83-99,  target='_blank' title='



Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
2. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
3. Medication Telemonitoring Improves Compliance and Behavior in NIH Study
4. Monitoring water through a snakes eyes
5. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
6. Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
7. Monitoring water through a snakes eyes
8. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
9. Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients
10. Monitoring water through a snakes eyes
11. Sixth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Chronic Care Management & Wellness Promotion
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading ... the Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio ... and clinical trial team. , Using the CONSULT module, patients and physicians can schedule ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):